MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
MYGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MYGN had positive earnings in the past year.
In the past year MYGN has reported a negative cash flow from operations.
MYGN had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: MYGN reported negative operating cash flow in multiple years.
1.2 Ratios
MYGN has a Return On Assets of -14.30%. This is amongst the best in the industry. MYGN outperforms 84.67% of its industry peers.
MYGN's Return On Equity of -20.96% is amongst the best of the industry. MYGN outperforms 85.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.3% | ||
| ROE | -20.96% | ||
| ROIC | N/A |
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MYGN's Gross Margin of 69.06% is amongst the best of the industry. MYGN outperforms 83.96% of its industry peers.
In the last couple of years the Gross Margin of MYGN has declined.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYGN has been increased compared to 1 year ago.
Compared to 5 years ago, MYGN has more shares outstanding
The debt/assets ratio for MYGN is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.54 indicates that MYGN is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.54, MYGN is doing good in the industry, outperforming 72.01% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that MYGN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.05, MYGN is not doing good in the industry: 61.85% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.54 |
ROIC/WACCN/A
WACC10.8%
2.3 Liquidity
A Current Ratio of 1.96 indicates that MYGN should not have too much problems paying its short term obligations.
MYGN's Current ratio of 1.96 is on the low side compared to the rest of the industry. MYGN is outperformed by 77.54% of its industry peers.
A Quick Ratio of 1.78 indicates that MYGN should not have too much problems paying its short term obligations.
MYGN has a worse Quick ratio (1.78) than 78.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 108.33% over the past year.
Looking at the last year, MYGN shows a quite strong growth in Revenue. The Revenue has grown by 14.78% in the last year.
The Revenue has been growing slightly by 0.25% on average over the past years.
EPS 1Y (TTM)108.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.5%
Revenue 1Y (TTM)14.78%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Sales Q2Q%15.26%
3.2 Future
MYGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.08% yearly.
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 7.14% on average per year.
EPS Next Y134.87%
EPS Next 2Y72.41%
EPS Next 3Y59.93%
EPS Next 5Y33.08%
Revenue Next Year11.99%
Revenue Next 2Y10.84%
Revenue Next 3Y10.32%
Revenue Next 5Y7.14%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 356.60, the valuation of MYGN can be described as expensive.
Based on the Price/Earnings ratio, MYGN is valued cheaper than 92.87% of the companies in the same industry.
MYGN is valuated expensively when we compare the Price/Earnings ratio to 30.20, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 65.49, which means the current valuation is very expensive for MYGN.
92.16% of the companies in the same industry are more expensive than MYGN, based on the Price/Forward Earnings ratio.
MYGN is valuated expensively when we compare the Price/Forward Earnings ratio to 23.28, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 356.6 | ||
| Fwd PE | 65.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MYGN's earnings are expected to grow with 59.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.64
PEG (5Y)N/A
EPS Next 2Y72.41%
EPS Next 3Y59.93%
5. Dividend
5.1 Amount
MYGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MYRIAD GENETICS INC
NASDAQ:MYGN (11/4/2024, 8:25:33 PM)
After market: 17.85 +0.02 (+0.11%)17.83
-0.16 (-0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.62B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 356.6 | ||
| Fwd PE | 65.49 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.64
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.3% | ||
| ROE | -20.96% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.06% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)108.33%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y134.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)14.78%
Revenue growth 3Y5.66%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y